Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (Clivarine) and polyethyleneglycol-hirudin

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 4, 1996, Pages 481-487

  Buchwald, Arnd B ^a   Hammerschmidt, Stefan ^a   Stevens, Jens ^a   Göring, Jens ^a   Nebendahl, Klaus ^a   Unterberg, Christina ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Clivarine; Coronary stents; Hirudin; Neointima; Polyethyleneglycol

Indexed keywords

HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LU 57291; MACROGOL; REVIPARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; STENT; SUBCUTANEOUS DRUG ADMINISTRATION; SWINE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; CELL DIVISION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; MUSCLE, SMOOTH, VASCULAR; SWINE; SWINE, MINIATURE;

EID: 0029738765     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199610000-00001     Document Type: Article

References (33)

1. Clowes AW, Karnovsky MJ. Suppression of heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-6.
2. Karnovsky MJ, Wright TC Jr, Castellot JJ, Choay J, Lormeau JC, Petitou M. Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis. Ann NY Acad Sci 1989;556:268-81.
3. Buchwald AB, Unterberg C, Nebendahl K, Gröne HJ, Wiegand V. Low-molecular weight heparin reduces neointimal proliferation after coronary stem implantation in hypercholesterolemic minipigs. Circulation 1992;86:531-7.
4. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:232-43.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
6. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991;88:10624-8.
7. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995;26:1747-54.
8. Jeske W, Blazejlowski BS, Walenga JM, Hoppenstaedt D, Ahsan A. Farced J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarine). Semin Thromb Hemost 1993;19(suppl 1):229-40.
9. Schmid KM, Preisack M, Voelker W, Sujatta M, Karsch KR. First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemostas 1993;19 (suppl 1):155-9.
10. Hanke H, Oberhoff M, Hanke S, et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation 1992;85:1548-55.
11. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-32.
12. Santoian EC, Schneider JE, Gravanis MB, et al. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993;88:11-4.
13. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-43.
14. Herrmann JPR, Hermans WRM, Vos J, Serruys PW. Pharmacologic approaches to the prevention of restenosis following angioplasty. Drugs 1993;46:18-52.
15. Serruys PW, De Jaegere P, Kiemeneji F, et al., for the Benestent Study Group. A comparison of balloon-expandable-plant implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
16. Fishman DL, Leon MB, Bairn DS, et al., for the Stent Restenosis Study Investigators. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
17. Waller BF. Coronary luminal shape and the arc of the disease-free wall: morphologic observations and clinical relevance. J Am Coll Cardiol 1985;6:1100-1.
18. Waller BF, Pinkerton CA, Orr CM, Slack JD, van Tassel JW, Peters T. Restenosis 1 to 24 months after clinically successful coronary balloon angioplusty: a necropsy study of 20 patients. J Am Coll Cardiol 1991;17:58B-70B.
19. Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation 1989;79:1374-87.
20. Bichler J, Siebeck M, Fichtl B, Fritz H. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Haemostasis 1991;21 (suppl 1):137-41.
21. Heras M, Chesebro JH, Webster MWI. et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990;82:1476-84.
22. Buchwald AB, Sandrock D, Unterberg C, et al. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993;21:249-54.
23. Rübsamen K. Hornberger W, Laux V, Schwarz M, Schweden J. Antithrombotic efficacy of the polyethyleneglycol-coupled hirudin LU 57291 in experimentally induced venous and arterial thrombosis [Abstract]. Thromb Hemost 1993;69:2717.
24. Esslinger HU, Dübbers K. Müller-Peltzer H. First data on safety and anticoagulant activity after single i.v. and s.c. PEG-hirudin administration in healthy volunteers [Abstract]. Thromb Hemost 1995;73:2109.
25. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
26. Ellis GS, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-82.
27. Hirsh J. Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
28. Lockner D. Bratt G, Tornebohm E, Aberg W. Pharmacokinetics of intravenously and subcutaneously administered fragmin in healthy volunteers. Haemostasis 1986;16(suppl 2):8-10.
29. Currier JW, Pow TK, Haudenschild CC, Minihan AC, Faxon DP. Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:118B-25B.
30. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation 1994;90:908-14.
31. Wallentin LC, Swahn E. FRISC: low molecular weight heparin (fragmin) during instability in coronary artery disease. Eur Heart J 1995;16(suppl):A2544.
32. Castellot JJ Jr, Cochran DL, Karnovsky MJ. Effect of heparin on vascular smooth muscle cells: I. Cell metabolism. J Cell Physiol 1985;124:21-8.
33. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.